These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 30303068)

  • 1. Age-related macular degeneration: treatment at what cost?
    The Lancet
    Lancet; 2018 Sep; 392(10153):1090. PubMed ID: 30303068
    [No Abstract]   [Full Text] [Related]  

  • 2. Time to ask patients about drugs for macular degeneration.
    Mackenzie JW
    BMJ; 2017 Nov; 359():j5426. PubMed ID: 29184013
    [No Abstract]   [Full Text] [Related]  

  • 3. Avastin is as effective as Lucentis in treating wet age related macular degeneration, study finds.
    Torjesen I
    BMJ; 2013 Jul; 347():f4678. PubMed ID: 23881948
    [No Abstract]   [Full Text] [Related]  

  • 4. Commentary: NHS patients should have a choice of drug for wet age-related macular degeneration, despite pressure from pharma.
    Hambleton D
    BMJ; 2017 Oct; 359():j5013. PubMed ID: 29089330
    [No Abstract]   [Full Text] [Related]  

  • 5. CCGs face legal threat for offering off-label drug for wet AMD.
    Cohen D
    BMJ; 2017 Oct; 359():j5021. PubMed ID: 29089307
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost comparison of ranibizumab and bevacizumab.
    Jackson TL; Kirkpatrick L
    BMJ; 2011 Aug; 343():d5058. PubMed ID: 21862536
    [No Abstract]   [Full Text] [Related]  

  • 7. Experience of New Brunswick ophthalmologists using intravitreal anti-vascular endothelial growth factor.
    Giberson M; Taylor V
    Can J Ophthalmol; 2015 Oct; 50(5):393-4. PubMed ID: 26455977
    [No Abstract]   [Full Text] [Related]  

  • 8. Are the odds shifting against pharma in the fight for cheaper treatment for macular degeneration?
    Cohen D
    BMJ; 2017 Oct; 359():j5016. PubMed ID: 29089312
    [No Abstract]   [Full Text] [Related]  

  • 9. A licence to cure.
    Aronson JK; Ferner RE
    BMJ; 2015 Apr; 350():h1723. PubMed ID: 25834026
    [No Abstract]   [Full Text] [Related]  

  • 10. Attacks on publicly funded trials: what happens when industry does not want to know the answer.
    Cohen D
    BMJ; 2015 Apr; 350():h1701. PubMed ID: 25834025
    [No Abstract]   [Full Text] [Related]  

  • 11. Anti-vascular endothelial growth factors treatment of wet age-related macular degeneration: from neurophysiology to cost-effectiveness.
    Vottonen P
    Acta Ophthalmol; 2018 Feb; 96 Suppl A109():1-46. PubMed ID: 29468838
    [No Abstract]   [Full Text] [Related]  

  • 12. [An eye for an eye? Lack of consensus in off-label use of medications leads to major regional differences in medical costs for the treatment of wet AMD in Sweden].
    Bro T
    Lakartidningen; 2017 Nov; 114():. PubMed ID: 29292948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ranibizumab (Lucentis) versus Bevacizumab (Avastin) for the Treatment of Age-Related Macular Degeneration: An Economic Disparity of Eye Health.
    Moreno TA; Kim SJ
    Semin Ophthalmol; 2016; 31(4):378-84. PubMed ID: 27116030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why have UK doctors been deterred from prescribing Avastin?
    Cohen D
    BMJ; 2015 Apr; 350():h1654. PubMed ID: 25834024
    [No Abstract]   [Full Text] [Related]  

  • 15. Provider, patient and public benefits from a NICE appraisal of bevacizumab (Avastin).
    Rhodes C; Harris J; Sulston J; Spanswick C
    J Med Ethics; 2012 Mar; 38(3):187-9. PubMed ID: 21947806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of treating wet age-related macular degeneration at the Kuopio University Hospital in Finland based on a two-eye Markov transition model.
    Vottonen P; Kankaanpää E
    Acta Ophthalmol; 2016 Nov; 94(7):652-656. PubMed ID: 27481048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Legal. PCTs taken to court over use of cheaper drug.
    Calkin S
    Health Serv J; 2012 Apr; 122(6303):10-1. PubMed ID: 22741353
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost comparison of intravitreal aflibercept with bevacizumab and ranibizumab for the treatment of wet age-related macular degeneration.
    Shaikh AH; Toussaint BW; Miller DM; Petersen MR; Foster RE; Riemann CD; Hutchins RK; Sisk RA
    Ophthalmic Surg Lasers Imaging Retina; 2015 Jan; 46(1):62-6. PubMed ID: 25559511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating age-related macular degeneration: comparing the use of two drugs among medicare and veterans affairs populations.
    Pershing S; Pal Chee C; Asch SM; Baker LC; Boothroyd D; Wagner TH; Bundorf MK
    Health Aff (Millwood); 2015 Feb; 34(2):229-38. PubMed ID: 25646102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High Variation of Intravitreal Injection Rates and Medicare Anti-Vascular Endothelial Growth Factor Payments per Injection in the United States.
    Erie JC; Barkmeier AJ; Hodge DO; Mahr MA
    Ophthalmology; 2016 Jun; 123(6):1257-62. PubMed ID: 26976701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.